Cerebrotendinous xanthomatosis tremor successfully controlled post-ventral intermediate nucleus-deep brain stimulation: a case report
- PMID: 37712087
- PMCID: PMC10498991
- DOI: 10.3389/fneur.2023.1243379
Cerebrotendinous xanthomatosis tremor successfully controlled post-ventral intermediate nucleus-deep brain stimulation: a case report
Abstract
Cerebrotendinous xanthomatosis (CTX) is a rare autosomal recessive disorder caused by a deficiency of the sterol 27-hydroxylase enzyme. This deficiency results in excess production and accumulation of cholestanol, which can lead to many clinical findings within the first three decades of life, including progressive neurological dysfunction. This is a treatable condition with improvements in neurological and non-neurological symptoms upon the early initiation of replacement therapy. This case report details a 42 years-old left-handed male in whom deep brain stimulation (DBS) intervention was pursued due to a limiting tremor related to delayed diagnosis and treatment of CTX at 22 years old. The application of DBS in treating tremors in a CTX patient has not previously been reported. For our patient, application of DBS led to meaningful and longstanding tremor control benefits that have required minimal changes to stimulation parameters post-DBS. These improvements to tremor were achieved without negative impact to his other CTX related comorbidities.
Keywords: cerebrotendinous xanthomatosis (CTX); deep brain stimulation (DBS); hyperkinetic movement disorder; lipid storage disease; tremor.
Copyright © 2023 Rich, Karakoleva, McInerney, Farace and De Jesus.
Conflict of interest statement
SDJ has received support unrelated to this research for her role as an Educational Consultant for Medtronic Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures


Similar articles
-
Cerebrotendinous xanthomatosis with tremor as the main manifestation: A case report.Medicine (Baltimore). 2024 Apr 26;103(17):e37976. doi: 10.1097/MD.0000000000037976. Medicine (Baltimore). 2024. PMID: 38669366 Free PMC article.
-
A case of Cerebrotendinous Xanthomatosis with spinal cord involvement and without tendon xanthomas: identification of a new mutation of the CYP27A1 gene.Acta Neurol Belg. 2021 Apr;121(2):561-566. doi: 10.1007/s13760-019-01267-4. Epub 2019 Dec 24. Acta Neurol Belg. 2021. PMID: 31875301
-
Cerebrotendinous Xanthomatosis: Molecular Pathogenesis, Clinical Spectrum, Diagnosis, and Disease-Modifying Treatments.J Atheroscler Thromb. 2021 Sep 1;28(9):905-925. doi: 10.5551/jat.RV17055. Epub 2021 May 8. J Atheroscler Thromb. 2021. PMID: 33967188 Free PMC article.
-
Cerebrotendinous xanthomatosis: a comprehensive review of pathogenesis, clinical manifestations, diagnosis, and management.Orphanet J Rare Dis. 2014 Nov 26;9:179. doi: 10.1186/s13023-014-0179-4. Orphanet J Rare Dis. 2014. PMID: 25424010 Free PMC article. Review.
-
[Pathophysiology of cerebrotendinous xanthomatosis].Rinsho Shinkeigaku. 2016 Dec 28;56(12):821-826. doi: 10.5692/clinicalneurol.cn-000962. Epub 2016 Nov 12. Rinsho Shinkeigaku. 2016. PMID: 27840382 Review. Japanese.
Cited by
-
Cerebrotendinous xanthomatosis with tremor as the main manifestation: A case report.Medicine (Baltimore). 2024 Apr 26;103(17):e37976. doi: 10.1097/MD.0000000000037976. Medicine (Baltimore). 2024. PMID: 38669366 Free PMC article.
References
-
- Patni N, Wilson DP. Cerebrotendinous xanthomatosis. South Dartmouth, MA, USA: MDText.com, Inc (2020).
-
- Federico A, Gallus GN. Cerebrotendinous xanthomatosis. University of Washington, Seattle: GeneReviews® [Internet]. (2003) 18:633–8.
Publication types
LinkOut - more resources
Full Text Sources